Celebrex Swiss Label Cites Clearly Lower Ulcer Rate Than Non-COX-2 NSAIDs
Executive Summary
Swiss labeling for the Searle/Pfizer COX-2 inhibitor Celebrex indicates a greater comfort with data showing that the new agents have a lower gastrointestinal ulcer rate than previously approved nonsteroidal anti-inflammatory agents.